A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study): A Turkish Oncology Group Study.,American Journal of Clinical Oncology

当前位置： X-MOL 学术 › Am. J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study): A Turkish Oncology Group Study.
American Journal of Clinical Oncology ( IF 1.6 ) Pub Date : 2021-05-12 , DOI: 10.1097/coc.0000000000000825
Huseyin Abali ₁ , Suayib Yalcin ₂ , Huseyin C Onal ₃ , Faysal Dane ₄ , Berna Oksuzoglu ₅ , Nuriye Ozdemir ₆ , Huseyin Mertsoylu ₇ , Mehmet Artac ₈ , Celaletdin Camci ₉ , Bulent Karabulut ₁₀ , Fatma B Basal ₅ , Burcin Budakoglu ₁₁ , Mehmet A N Sendur ₁₂ , Burce Goktas ₁₃ , Fatih Ozdener ₁₄ , Arzu Baygul ₁₅

Affiliation

Department of Medical Oncology, Acibadem Adana Hospital.
Department of Medical Oncology, Hacettepe University.
Departments of Radiation.
Department of Medical Oncology, Marmara University.
Department of Medical Oncology, Dr. A.Y. Ankara Oncology Training and Research Hospital.
Department of Medical Oncology, Gazi University.
Medical Oncology, Baskent University, Adana.
Department of Medical Oncology, Necmettin Erbakan University Meram School of Medicine, Konya.
Department of Medical Oncology, Ethica Incirli Hospital.
Department of Medical Oncology, Ege University, Izmir, Turkey.
Department of Medical Oncology, Medical Park Ankara Hospital.
Department of Medical Oncology, Ankara Yildirim Beyazit University, Ankara.
Roche Pharmaceuticals.
Department of Medical Pharmacology, Bahcesehir University School of Medicine.
Department of Biostatistics and Medical Informatics, Koc University/MedStats Consulting, Istanbul.

Trastuzumab prolonged the overall survival in patients with advanced gastric cancer with human epidermal growth factor receptor 2 (HER2) overexpression in combination with chemotherapy. In this phase II open-label prospective study, the tolerability and safety of trastuzumab with chemotherapy, and chemoradiotherapy for curatively resected patients with HER2-positive gastric carcinoma was investigated.

中文翻译：

奥沙利铂、卡培他滨和曲妥珠单抗联合放化疗辅助治疗 HER2 阳性胃癌或胃食管结合部癌手术患者的 II 期研究（TOXAG 研究）：土耳其肿瘤学组研究。

曲妥珠单抗延长了人表皮生长因子受体 2 (HER2) 过度表达的晚期胃癌患者的总生存期，并与化疗相结合。在这项 II 期开放标签前瞻性研究中，研究了曲妥珠单抗联合化疗和放化疗对治愈性切除的 HER2 阳性胃癌患者的耐受性和安全性。

更新日期：2021-05-14

点击分享查看原文

点击收藏

阅读更多本刊最新论文